Everest Medicines Secures China Approval for Ulcerative Colitis Drug VELSIPITY®
Event summary
- Everest Medicines received NMPA approval for VELSIPITY® (etrasimod) for treating moderately to severely active ulcerative colitis (UC) in adult patients.
- The approval is based on the Asian ENLIGHT UC Phase 3 trial (340 patients) and the global ELEVATE UC Phase 3 program.
- The ENLIGHT UC study demonstrated statistically significant improvements across all primary and secondary efficacy endpoints.
- VELSIPITY® is the first Phase 3 registrational study in Asian patients with moderately to severely active UC.
- The drug has also been included in clinical guidelines from the AGA and ACG.
The big picture
The approval of VELSIPITY® represents a significant win for Everest Medicines, positioning them as a key player in the rapidly growing Chinese UC market, which is projected to reach 1.5 million patients by 2031. The drug's S1P receptor modulation mechanism and demonstrated mucosal healing efficacy address a critical unmet need, particularly given the rising incidence of UC in younger Chinese patients. However, success hinges on navigating China’s complex regulatory and reimbursement environment and competing against established biologic therapies.
What we're watching
- Reimbursement
- The company's efforts to secure inclusion on the National Reimbursement Drug List will be critical for driving adoption and revenue generation in China.
- Competition
- The emergence of VELSIPITY® will intensify competition within the UC treatment landscape, potentially impacting pricing and market share for existing therapies.
- Commercialization
- The speed and effectiveness of Everest Medicines’ commercialization strategy will determine how quickly VELSIPITY® penetrates the Chinese market and achieves its revenue potential.
Related topics